Immunohistochemical detection of advanced glycation end products in dialysis-related amyloidosis

52Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

β2-Microglobulin (β2m) isolated from the amyloid deposits in patients with dialysis-related amyloidosis (DRA) has been demonstrated to be modified with advanced glycation end products (AGE). We produced a monoclonal anti-AGE antibody which localized AGE to amyloid deposits in patients with DRA by immunohistochemistry. The connective tissues in the carpal tunnel were obtained from surgical specimens in six patients with DRA. AGE were localized to the β2-m-positive amyloid deposits in these patients using the monoclonal anti-AGE antibody. AGE were also detected in infiltrating cells surrounding the amyloid deposits. The AGE-positive cells were identified as macrophages, since they showed positive staining with anti-CD68 antibody. In conclusion, AGE were demonstrated by immunohistochemical technique to be present in both P,m-positive amyloid deposits and surrounding macrophages in patients with DRA.

Cite

CITATION STYLE

APA

Niwa, T., Miyazaki, S., Katsuzaki, T., Tatemichi, N., Takei, Y., Miyazaki, T., … Hirasawa, Y. (1995). Immunohistochemical detection of advanced glycation end products in dialysis-related amyloidosis. Kidney International, 48(3), 771–778. https://doi.org/10.1038/ki.1995.349

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free